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We acknowledge Antonuzzo and colleagues for their correspon-
dence in the Journal (1), reporting for the first time a case of
osteonecrosis of jaw (ONJ) after regorafenib treatment: Their re-
port is robust and adds to the growing knowledge about this se-
rious complication. However, in our opinion, some details are
missing in order to establish a clear relationship between ONJ
and regorafenib exposure.
Previous anticancer treatment should be reported.
Regorafenib is usually prescribed as third or further line treat-
ment of metastatic colorectal cancer after standard therapy, in-
cluding chemotherapy (oxaliplatin- and irinotecan-based
schemes) and biologicals (bevacizumab or aflibercept, and/or
anti–epidermal growth factor receptor [EGFR] agents in case of
all-RAS wild-type status). Readers should be informed if the pa-
tient received an antiangiogenic agent such as bevacizumab or
aflibercept previously. These drugs have been associated with
ONJ (2–4). Therefore, it is important to know whether the patient
has been exposed to bevacizumab or aflibercept. If this is the
case, important information such as exposure time prior to
regorafenib, time on the medication, dosing schedule, and cu-
mulative dose are needed.
Furthermore, dental history and the presence of dental dis-
ease are important risk factors for ONJ (2). Thus, the report
should provide a detailed history about oral health and dental
disease such as endodontic or periodontal infections and the
presence of ill-fitting dentures prior to regorafenib treatment.
Did the patient receive routine dental evaluation and x-rays be-
fore or during the therapy with regorafenib, and/or any previous
antiangiogenic drug treatment? It is also very interesting to
know whether any dentoalveolar surgical procedure (eg, tooth
extraction, implants) was performed before, during, or after
regorafenib administration.
Because medication-related ONJ is still highly debated, even
in the definition and frequency estimations (5), well-docu-
mented case reports of ONJ after nonantiresorptive drugs, in-
cluding clinical history and imaging, are welcome in the
absence of large and prospective studies in this setting.
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